PMID- 28516675
OWN - NLM
STAT- MEDLINE
DCOM- 20181025
LR  - 20181025
IS  - 1365-3148 (Electronic)
IS  - 0958-7578 (Linking)
VI  - 28
IP  - 1
DP  - 2018 Feb
TI  - Analysis of platelet-reactive alloantibodies and evaluation of 
      cross-match-compatible platelets for the management of patients with transfusion 
      refractoriness.
PG  - 40-46
LID - 10.1111/tme.12423 [doi]
AB  - BACKGROUND: Cross-match-compatible platelets can improve corrected count 
      increments (CCIs) in alloimmunised patients with transfusion refractoriness. 
      However, only a few studies mentioned that the specificities of platelet-reactive 
      alloantibodies can predict high reactivity in cross-match assays among these 
      patients. METHODS: A total of 204 medical records of patients who were refractory 
      to random single-donor apheresis platelets between January 2014 and December 2014 
      were enrolled. Platelet-reactive antibodies in patients' serum were screened by 
      an enzyme-linked immunosorbent assay (ELISA).The platelet cross-match assays were 
      performed by a solid-phase adherence assay. The specificities of human leukocyte 
      antigen (HLA) class I and human platelet antigens (HPAs) alloantibodies were 
      determined by Luminex Single Antigen and Monoclonal Antibody-specific 
      Immobilization of Platelet Antigens (MAIPA) assays, respectively. RESULTS: 
      Anti-HLA and anti-HPA alloantibodies were found in 114 of 204 (55.88%) patients, 
      including 110 (96.49%) with anti-HLA alloantibodies only, 2 (1.75%) with anti-HPA 
      alloantibodies (anti-GPIIb/IIIa) only and 2 (1.75%) with both anti-HLA and 
      anti-HPA alloantibodies (anti-HPA-3a and anti-HPA-5b). The most common HLA class 
      I alloantibody phenotypes in cross-match-incompatible patients were HLA-A23 
      (59.38%), -A24 (50.00%), -A02 (43.75%), -B27 (65.63%), -B40 (50.00%), -B18 
      (46.88%) and -B07 (43.75%). A total of 480 cross-matched platelet units were 
      administered in 82 of 114 alloimmunised patients with a mean CCI of 7800 +/- 5200, 
      a significant improvement over random platelet units (P < 0.001). CONCLUSIONS: No 
      development of additional platelet alloantibodies was observed during this 
      platelet transfusion regiment. This study showed that transfusion of 
      cross-match-compatible platelet units offers effective and safe management of 
      platelet transfusion refractoriness (PTR). The finding of alloantibodies among 
      cross-match-incompatible cases can be used as predictors for platelet donor 
      selection.
CI  - (c) 2017 British Blood Transfusion Society.
FAU - Wang, J
AU  - Wang J
AUID- ORCID: 0000-0001-6466-8585
AD  - Institute of Blood Transfusion, Guangzhou Blood Center, Guangzhou, Guangdong, 
      China.
FAU - Xia, W
AU  - Xia W
AD  - Institute of Blood Transfusion, Guangzhou Blood Center, Guangzhou, Guangdong, 
      China.
FAU - Deng, J
AU  - Deng J
AD  - Institute of Blood Transfusion, Guangzhou Blood Center, Guangzhou, Guangdong, 
      China.
FAU - Xu, X
AU  - Xu X
AD  - Institute of Blood Transfusion, Guangzhou Blood Center, Guangzhou, Guangdong, 
      China.
FAU - Shao, Y
AU  - Shao Y
AD  - Institute of Blood Transfusion, Guangzhou Blood Center, Guangzhou, Guangdong, 
      China.
FAU - Ding, H
AU  - Ding H
AD  - Institute of Blood Transfusion, Guangzhou Blood Center, Guangzhou, Guangdong, 
      China.
FAU - Chen, Y
AU  - Chen Y
AD  - Institute of Blood Transfusion, Guangzhou Blood Center, Guangzhou, Guangdong, 
      China.
FAU - Liu, J
AU  - Liu J
AD  - Institute of Blood Transfusion, Guangzhou Blood Center, Guangzhou, Guangdong, 
      China.
FAU - Chen, D
AU  - Chen D
AD  - Institute of Blood Transfusion, Guangzhou Blood Center, Guangzhou, Guangdong, 
      China.
FAU - Ye, X
AU  - Ye X
AD  - Institute of Blood Transfusion, Guangzhou Blood Center, Guangzhou, Guangdong, 
      China.
FAU - Santoso, S
AU  - Santoso S
AD  - Institute of Blood Transfusion, Guangzhou Blood Center, Guangzhou, Guangdong, 
      China.
AD  - Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig 
      University, Giessen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20170518
PL  - England
TA  - Transfus Med
JT  - Transfusion medicine (Oxford, England)
JID - 9301182
RN  - 0 (Antigens, Human Platelet)
RN  - 0 (HLA Antigens)
RN  - 0 (Isoantibodies)
SB  - IM
MH  - Adult
MH  - Antigens, Human Platelet/blood/*immunology
MH  - Blood Platelets/*immunology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - HLA Antigens/blood/*immunology
MH  - Humans
MH  - Isoantibodies/blood/*immunology
MH  - Male
MH  - *Platelet Transfusion
OTO - NOTNLM
OT  - HLA class I antibody
OT  - cross-match-compatible platelet
OT  - platelet transfusion refractoriness
OT  - platelet-specific antibody
EDAT- 2017/05/19 06:00
MHDA- 2018/10/26 06:00
CRDT- 2017/05/19 06:00
PHST- 2016/06/08 00:00 [received]
PHST- 2017/02/27 00:00 [revised]
PHST- 2017/04/22 00:00 [accepted]
PHST- 2017/05/19 06:00 [pubmed]
PHST- 2018/10/26 06:00 [medline]
PHST- 2017/05/19 06:00 [entrez]
AID - 10.1111/tme.12423 [doi]
PST - ppublish
SO  - Transfus Med. 2018 Feb;28(1):40-46. doi: 10.1111/tme.12423. Epub 2017 May 18.